Skip to main content
. Author manuscript; available in PMC: 2019 Mar 1.
Published in final edited form as: Gut. 2016 Nov 7;67(3):473–484. doi: 10.1136/gutjnl-2016-312794

Table 1.

Characteristics of human subjects and plasma samples

A. Prediagnostic samples (Cardiovascular Health Study population)

Cases (n=79) Controls (n=79)
79 matched pair N % N %
Sex
  Male 44 55.7 44 55.7
  Female 35 44.3 35 44.3

Age
  65–69 21 26.6 21 26.6
  70–74 30 38 33 41.8
  75–79 21 26.6 18 22.8
  >80 7 8.9 7 8.9

Race
  White 70 88.6 70 88.6
  Black 9 11.4 9 11.4

BMI
  Normal (19.0–24.9) 33 41.8 24 30.4
  Overweight (25.0–29.9) 27 34.2 38 48.1
  Obese (30.0-) 19 24.1 17 21.5

Cancer diagnosed after blood draw
<2 years 67 84.8
>2 years, <3 years 12 15.2

Cancer sites
  Proximal 25 31.6
  Distal 42 53.2
  Proximal & distal 2 2.2
  Rectal 10 12.7
B. Diagnostic samples (Early Detection Research Network study population)

Adenomas (n=60) Cancers (n=60) Controls (n=60)
n % n % n %
Sex
  Male 29 48.3 34 56.7 16 26.7
  Female 31 51.7 26 43.3 44 73.3

Age
  30–39 1 1.7 1 1.7 3 5
  40–49 2 3.3 12 20 8 13.3
  50–59 23 38.3 12 20 30 50
  60–69 21 35 13 21.7 14 23.3
  70–79 10 16.7 13 21.7 5 8.3
  >80 3 5 9 15 0 0

Stages
Adenoma 30 50
  Advanced adenoma* 30 50
  I 11 18.3
  IIa 17 28.3
  IIb 2 3.3
  IIIa 6 10
  IIIb 10 16.7
  IIIc 5 8.3
  IV 9 15
C. PRoBE-compliant Diagnostic samples (Japanese study population)

Cancers (n=514) Normal
Controls
(n=168)
Low CRC risk
Controls (n=159)
Ulcerative
Colitis (n=59)
n % n % n % N %
Sex
Male 296 57.6 94 56 102 64.2 35 59.3
Female 218 42.4 74 44 57 35.8 24 40.7

Age
<40 3 0.6 19 11.3 4 2.5 24 40.7
40–49 20 3.9 23 13.7 15 9.4 11 18.6
50–59 57 11.1 29 17.3 17 10.7 13 22
60–69 138 26.8 41 24.4 53 33.3 5 8.5
70–79 169 32.9 46 27.4 54 34 5 8.5
>80 127 24.7 10 6 16 10.1 1 1.7

Stages
I 114 22.2
II 37 7.2
IIa 104 20.2
IIb 10 1.9
IIc 4 0.8
III 1 0.2
IIIa 43 8.4
IIIb 77 15
IIIc 26 5.1
IV 74 14.4
Iva 10 1.9
IVb 14 2.7
*

Advanced adenoma: see definition above